Segluromet Approval History
Segluromet (ertugliflozin and metformin hydrochloride) is a sodium glucose co-transporter 2 (SGLT2) inhibitor and biguanide combination used to improve glycemic control in adults with type 2 diabetes.
Development History and FDA Approval Process for Segluromet
|Dec 22, 2017||FDA Approves Segluromet (ertugliflozin and metformin hydrochloride) for Type 2 Diabetes|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.